To assess the safety and the efficacy of Highly Active Anti-Retroviral Treatment (HAART) for the Prevention of Mother-To-Child Transmission of HIV (PMTCT)
1. To describe characteristics of HIV-infected pregnant women who request HAART from the Thai Red Cross Society PMTCT (TRCS PMTCT) program 2. To study adverse pregnancy outcomes among HIV-infected pregnant women who receive HAART 3. To study adverse events in infants born to women who receive HAART during pregnancy 4. To evaluate risk factors for HAART-related toxicities and for perinatal HIV transmission 5. To establish the pilot model of care for HIV-infected pregnant women in middle income country
Study Type
OBSERVATIONAL
Enrollment
250
The Thai Red Cross AIDS Research Centre
Pathum Wan, Bangkok, Thailand
HIV-infected pregnant women
Choose to start HAART according to protocol and do not want to receive antiretroviral treatment provided by the other health care systems
Time frame: 18 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.